# IGC Pharma Inc. (IGC)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $22M  
**Price:** $0.29 (+3.20%)

> IGC Pharma Inc. is a pharmaceutical and biotechnology company focused on the development and commercialization of innovative therapies for the treatment of chronic pain, cancer, and other life-altering conditions. The company's primary role involves leveraging unique approaches to drug development, particularly using cannabinoids, to create novel solutions that address unmet medical needs. IGC Pharma operates within the biotech sector, which is marked by significant research and development activities and a robust pipeline of products at various stages of clinical trials. 

Notably, IGC Pharma's initiatives in the pharmaceutical industry aim at integrating traditional pharmaceutical methods with new advancements in cannabinoid science. This positions the company as a potential influencer in sectors such as pain management and oncology, where treatment options are continually evolving. Due to its focus on strategic research and development, IGC Pharma plays a crucial role in the broader biotechnology market, aiming to introduce cutting-edge therapies that can change the standard of care for complex medical conditions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1M | $619,000 | -$7M | -$7M | $-0.09 |
| 2024 | $1M | $733,000 | -$10M | -$13M | $-0.22 |
| 2023 | $911,000 | $442,000 | -$12M | -$12M | — |
| 2022 | $397,000 | $194,000 | -$15M | -$15M | — |
| 2021 | $898,000 | $113,000 | -$9M | -$9M | — |
| 2020 | $4M | $115,000 | -$7M | -$7M | — |
| 2019 | $5M | $132,000 | -$5M | -$4M | — |
| 2018 | $2M | $82,000 | -$2M | -$2M | — |
| 2017 | $580,372 | $218,237 | -$2M | -$2M | $-0.07 |
| 2016 | $6M | $843,294 | -$3M | -$3M | $-0.17 |
| 2015 | $8M | $579,689 | -$4M | -$5M | $-0.31 |
| 2014 | $2M | $381,596 | -$3M | -$3M | $-0.37 |
| 2013 | $8M | $2M | -$2M | -$2M | $-0.32 |
| 2012 | $4M | -$618,429 | -$8M | -$8M | $-2.66 |
| 2011 | $4M | $159,264 | -$16M | -$20M | $-1.34 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $9M | $2M | $6M | $405,000 | $134,000 |
| 2024 | $10M | $3M | $7M | $1M | $137,000 |
| 2023 | $17M | $2M | $15M | $3M | $141,000 |
| 2022 | $27M | $3M | $24M | $10M | $144,000 |
| 2021 | $36M | $3M | $33M | $15M | $276,000 |
| 2020 | $29M | $2M | $27M | $7M | — |
| 2019 | $34M | $893,000 | $34M | $26M | — |
| 2018 | $11M | $3M | $8M | $2M | — |
| 2017 | $11M | $4M | $7M | $538,000 | $452,080 |
| 2016 | $19M | $5M | $13M | $1M | $801,467 |
| 2015 | $20M | $6M | $14M | $824,492 | $323,904 |
| 2014 | $18M | $4M | $14M | $1M | — |
| 2013 | $19M | $4M | $14M | $1M | — |
| 2012 | $25M | $9M | $15M | $562,948 | — |
| 2011 | $18M | $8M | $7M | $2M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$5M | $112,000 | -$5M |
| 2024 | -$5M | $138,000 | -$5M |
| 2023 | -$7M | $310,000 | -$7M |
| 2022 | -$7M | $236,000 | -$8M |
| 2021 | -$11M | $1M | -$12M |
| 2020 | -$9M | $4M | -$13M |
| 2019 | -$3M | $15,000 | -$3M |
| 2018 | -$2M | $136,000 | -$2M |
| 2017 | -$1M | $145,677 | -$2M |
| 2016 | -$157,702 | $122,185 | -$279,887 |
| 2015 | -$3M | $76,527 | -$3M |
| 2014 | -$2M | $8,485 | -$2M |
| 2013 | $564,845 | $326,078 | $238,767 |
| 2012 | -$5M | $5,480 | -$5M |
| 2011 | -$3M | $285,441 | -$3M |

Source: [CompaniesByCap](https://companiesbycap.com/company/IGC)